Aquestive Therapeutics, Inc. (AQST): Total Liabilities
$194.09M
As of 2025-12-31
$188.69M
As of 2026-06-30
+3.4%
3-year compound annual growth
+11.7%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $194.09M | +20.1% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $161.58M | -1.4% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $163.91M | -6.7% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $175.62M | +21.9% | 2024-03-05, Balance as of period end |
| 2021-12-31 | $144.13M | +29.4% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $111.38M | +31.7% | 2022-03-08, Balance as of period end |
| 2019-12-31 | $84.60M | +10.2% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $76.77M | +10.3% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $69.61M | n/a | 2019-03-14, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | 2025-12-31 | $194.09M | +20.1% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $52.28M | -1.4% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $7.67M | +67.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $119.41M | +123.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $53.48M | -23.0% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $112.27M | -16.7% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $18.08M | +2.4% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | $295.01M | +3.2% |
Compare AQST, CPIX, INBP, XLO side by side · Screen every company in Pharmaceutical Preparations ↗